Role of Glucose-Lowering Medications in Erectile Dysfunction
Open accessThe DOI matches its Crossref record; 183 of the 184 references it cites were found in a registry or an index.
Abstract
Erectile dysfunction (ED) is a long-term complication of type 2 diabetes (T2D) widely known to affect the quality of life. Several aspects of altered metabolism in individuals with T2D may help to compromise the penile vasculature structure and functions, thus exacerbating the imbalance between smooth muscle contractility and relaxation. Among these, advanced glycation end-products and reactive oxygen species derived from a hyperglycaemic state are known to accelerate endothelial dysfunction by lowering nitric oxide bioavailability, the essential stimulus of relaxation. Although several studies have explained the pathogenetic mechanisms involved in the generation of erectile failure, few studies to date have described the efficacy of glucose-lowering medications in the restoration of normal sexual activity. Herein, we will present current knowledge about the main starters of the pathophysiology of diabetic ED and explore the role of different anti-diabetes therapies in the potential remission of ED, highlighting specific pathways whose activation or inhibition could be fundamental for sexual care in a diabetes setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“liraglutide improved ED by regulating smooth muscle dysfunction and oxidative stress in a GLP-1 receptor-dependent fashion in a rat model of type 1 diabetes99.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [99]
In the citing paper
“the GLP-1 receptor was detected in endothelial cells and GLP-1RA were found to affect endothelial function by stimulating nitric oxide production99.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543 · cited 1×
“In addition, this drug could also reduce the incidence of newly diagnosed diabetes among individuals with impaired glucose tolerance [105].”
BackgroundChiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624 · cited 1×
“In an international, multicentre double-blind, placebo-controlled randomised trial, ACA-based therapy demonstrated a cardioprotective role [106], possibly caused by the prevention of endothelial cell dysfunction [107] in both individuals with impaired glucose tolerance and new-onset T2D.”
BackgroundControl of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
Augustin, H. G., Young Koh, G., Thurston, G., & Alitalo, K. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2639 · Cited by 1,465 · cited 1×
“Additionally, the maintenance of endothelial integrity needs the balance between the angiopoietin growth factor-1 (Ang-1), which favours vessel integrity and endothelial cell renewal through Tie-2 receptor activation [20], and the angiopoietin growth factor-2 (Ang-2), having a proangiogenic and proinflammatory action…”
BackgroundIncalza, M. A., D'Oria, R., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2017.05.005 · Cited by 1,356
Self-citationDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus
Nowotny, K., Jung, T., Höhn, A., Weber, D., & Grune, T. (2015) · Biomolecules · doi:10.3390/biom5010194 · Cited by 1,095
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Fiedler, U., Reiss, Y., Scharpfenecker, M., Grunow, V., Koidl, S., Thurston, G., Gale, N. W., Witzenrath, M., Rosseau, S., Suttorp, N., et al. (2006) · Nature Medicine · doi:10.1038/nm1351 · Cited by 933 · cited 1×
“Additionally, the maintenance of endothelial integrity needs the balance between the angiopoietin growth factor-1 (Ang-1), which favours vessel integrity and endothelial cell renewal through Tie-2 receptor activation [20], and the angiopoietin growth factor-2 (Ang-2), having a proangiogenic and proinflammatory action…”
Backgroundon behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Research works printed but not linked: 1
- (2021, April 14). Mechanism of Action of Inhibitors of Dipeptidyl-Peptidase-4 (DPP-4) | Elsevier Enhanced Reader. Available online: https://reader.elsevier.com/reader/sd/pii/S1521690X09000232?token=CD1B2CAC3076F481A8BBC18456AF1EF7A483BCC4BD49BB908C4B2A0F620E9D0218ADAEFBC0CDE9B573BAEAE798A9DB99&originRegion=eu-west-1&originCreation=20210414141938.
Cited by
Adipose Tissue Dysfunction and Obesity-Related Male Hypogonadism
Genchi, V. A., Rossi, E., Lauriola, C., D’Oria, R., Palma, G., Borrelli, A., Caccioppoli, C., Giorgino, F., & Cignarelli, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158194 · Cited by 175
“Recently, the positive effects of GLP-1RA on both male fertility and AT health in obese men have been reported [6,96].”
BackgroundSelf-citationIncretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48
“For instance, liraglutide improved ED by regulating smooth muscle dysfunction and oxidative stress in a GLP-1 receptor-dependent fashion in a rat model of type 1 diabetes 99 .”
Self-citationEffects of diet and antihyperglycemic drugs on erectile dysfunction: A systematic review
Defeudis, G., Mazzilli, R., Tommaso, A. M. D., Zamponi, V., Carlomagno, F., Tuccinardi, D., Watanabe, M., Faggiano, A., & Gianfrilli, D. (2022) · Andrology · doi:10.1111/andr.13192 · Cited by 35
Defeudis, G., Tommaso, A. M. D., Rosa, C. D., Cimadomo, D., Khazrai, Y. M., Faggiano, A., Cincione, R. I., Napoli, N., & Mazzilli, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123382 · Cited by 35
Sun, T., Xu, W., Wang, J., Wang, T., Wang, S., Liu, K., & Liu, J. (2022) · Andrology · doi:10.1111/andr.13296 · Cited by 25
Metadata
- Authors
- Cignarelli, A., Genchi, V. A., D’Oria, R., Giordano, F., Caruso, I., Perrini, S., Natalicchio, A., Laviola, L., & Giorgino, F.
- Affiliations
- University of Bari Aldo Moro (IT)
- Corresponding author
- Giorgino, Francesco
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-06-05
- Volume
- 10
- Issue
- 11
- Pages
- 2501
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC8201035
- OpenAlex
- W3168626846
- Cited by
- 30
- References
- 184
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 7 · 2023: 6 · 2022: 7
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- erectile dysfunction, type 2 diabetes, glucose-lowering medications, advanced glycation end products, reactive oxygen species, endothelial dysfunction, nitric oxide bioavailability, smooth muscle contractility, sexual function
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Glucose-Lowering Medications in Erectile Dysfunction. https://app.cochat.ai/papers/10.3390/jcm10112501
- The paper
- Cignarelli, A., Genchi, V. A., D’Oria, R., Giordano, F., Caruso, I., Perrini, S., Natalicchio, A., Laviola, L., & Giorgino, F. (2021). Role of Glucose-Lowering Medications in Erectile Dysfunction. Journal of Clinical Medicine. https://doi.org/10.3390/jcm10112501
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.